Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

v3.21.1
Segments (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
  For the three months ended March 31,
(In thousands) 2021 2020
Revenue from services:
Pharmaceutical $ —  $ — 
Diagnostics 506,951  170,839 
Corporate —  — 
$ 506,951  $ 170,839 
Revenue from products:
Pharmaceutical $ 33,945  $ 31,074 
Diagnostics —  — 
Corporate —  — 
$ 33,945  $ 31,074 
Revenue from transfer of intellectual property and other:
Pharmaceutical $ 4,269  $ 9,553 
Diagnostics —  — 
Corporate —  — 
$ 4,269  $ 9,553 
Operating income (loss):
Pharmaceutical $ (19,157) $ (14,126)
Diagnostics 67,014  (18,133)
Corporate (9,420) (8,503)
$ 38,437  $ (40,762)
Depreciation and amortization:
Pharmaceutical $ 7,413  $ 7,121 
Diagnostics 12,576  14,871 
Corporate —  60 
$ 19,989  $ 22,052 
Loss from investment in investees:
Pharmaceutical $ (43) $ (134)
Diagnostics —  — 
Corporate —  — 
$ (43) $ (134)
Revenues:
United States $ 512,871  $ 180,872 
Ireland 7,129  11,901 
Chile 14,152  10,850 
Spain 5,919  4,156 
Israel 2,512  1,707 
Mexico 2,418  1,841 
Other 164  139 
$ 545,165  $ 211,466 
(In thousands) March 31,
2021
December 31,
2020
Assets:
Pharmaceutical $ 1,151,771  $ 1,176,245 
Diagnostics 1,330,183  1,268,738 
Corporate 37,621  28,080 
$ 2,519,575  $ 2,473,063 
Goodwill:
Pharmaceutical $ 241,353  $ 245,793 
Diagnostics 434,809  434,809 
Corporate —  — 
$ 676,162  $ 680,602